Kamada

Healthcare · Drug Manufacturers - Specialty & Generic

8.20$ -3.1% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Income Statement

Kamada (KMDA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 55 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement KMDA
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	19	24	12	33	23	36	17	34	15	48	27	35	33	32	33	33	35	32	25	24	23	31	28	24	32	45	31	37	38	36	38	42	42	39	44	45	47	45	45	55	192
Cost of Revenue	13	19	9.4	21	16	24	10	23	12	27	16	22	20	20	22	22	21	21	16	15	17	25	17	16	19	30	19	23	23	22	21	24	25	22	23	26	27	28	26	32	114
Gross Profit	6.3	5.0	2.3	12	6.4	12	7.0	11	2.5	21	11	14	13	12	11	11	15	10	8.9	9.1	5.7	6.6	11	7.2	13	15	12	14	15	14	17	19	17	17	21	19	20	17	19	22	78
Research & Development	4.4	4.2	3.2	3.5	3.4	1.9	2.8	2.4	2.3	2.6	2.8	3.5	3.5	3.3	3.3	3.6	3.4	3.3	2.6	2.7	2.5	3.4	4.4	2.6	3.1	3.0	3.2	4.3	3.2	3.2	4.3	4.8	3.4	2.7	4.2	3.2	2.6	2.9	2.2	2.2	9.9
Selling, General & Administrative	2.0	2.0	1.8	2.1	2.3	2.0	2.1	2.2	1.9	2.4	2.1	2.5	2.2	1.6	2.3	2.3	2.5	2.2	2.8	3.3	2.7	3.0	3.0	3.3	3.2	6.4	3.4	3.5	3.7	7.7	3.8	3.8	4.0	8.8	4.2	4.1	4.8	11	5.2	5.8	27
Total Operating Expenses	7.3	6.9	6.0	6.7	6.8	5.2	5.8	5.5	5.0	5.9	6.0	7.2	7.2	6.6	6.6	7.1	7.1	7.5	6.6	8.0	6.5	9.9	11	9.5	10	11	12	12	10	12	13	13	12	12	13	12	12	13	12	13	50
Operating Income	-1.0	-1.9	-3.7	5.0	-0.3	6.4	1.2	5.2	-2.5	15	5.2	6.4	5.7	5.5	4.9	4.0	7.8	2.6	2.4	1.0	-0.8	-3.3	0.2	-2.3	2.6	4.0	0.3	2.6	4.4	2.8	4.0	5.6	5.3	5.1	7.8	7.1	7.8	3.6	7.0	9.5	28
Interest Expense	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.1	0.2	0.2	0.2	0.3	0.5	0.4	0.4	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.4	1.0
Pre-Tax Income	-1.0	-1.6	-3.9	4.9	-0.2	6.4	1.3	5.7	-2.4	16	5.1	6.4	6.0	5.5	5.6	3.8	7.2	1.9	2.7	0.9	-0.8	-4.7	-1.8	-3.9	0.5	2.9	-1.8	1.9	3.3	5.0	2.4	4.5	3.9	2.5	6.6	5.8	6.4	4.7	5.4	10	27
Income Tax Expense	0.0	0.2	0.1	0.2	0.0	0.2	0.0	0.0	-0.1	-1.9	0.1	0.2	0.2	0.2	0.4	0.4	0.3	0.3	-0.3	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	-1.3	2.6	-1.6	1.1	1.2	1.3	0.9	4.4
Net Income	-1.0	-1.8	-4.0	4.9	-0.2	6.3	1.3	5.7	-2.4	18	4.9	6.1	5.8	5.4	5.2	3.5	6.8	1.6	2.7	0.9	-0.8	-5.0	-1.8	-3.9	0.5	2.9	-1.8	1.8	3.2	5.1	2.4	4.4	3.9	3.8	4.0	7.4	5.3	3.6	4.1	9.3	22
EBITDA	-0.1	-0.6	-3.0	5.9	0.7	7.3	2.2	6.2	-1.4	16	6.3	7.6	7.2	6.7	6.9	5.1	8.5	3.2	3.9	2.2	0.5	-1.6	1.4	-0.7	3.8	6.3	1.8	5.5	6.9	8.2	5.8	7.9	7.4	6.7	10	9.7	10	8.8	9.4	13	42

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings